DelveInsight’s, “TCR Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 35+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including TCR Therapy clinical trials and nonclinical stage products. It also covers the TCR Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the TCR Therapy pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, TCR Therapy clinical trials studies, TCR Therapy NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
Key takeaways from the TCR Therapy Pipeline Report
To explore more information on the latest breakthroughs in the TCR Therapy Pipeline treatment landscape of the report, click here @ TCR Therapy Pipeline Outlook
TCR Therapy Overview
T-cell receptor (TCR)-based adaptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process that involves patient screening (e.g., for HLA-A*02:01 and specific tumor targets), leukapheresis, generation of transduced TCR product, lymphodepletion, and infusion of the TCR-based adoptive therapy. The majority of TCR structures are heterodimers comprised of α- and β-chains that are covalently linked via a disulfide bond between the conserved cysteine residues located within the constant region of each chain. Adoptive cell therapy (ACT), which uses genetically engineered human lymphocytes, is increasingly being investigated in patients with hematologic malignancies and solid tumors. The implementation of TCR Therapy will require a shortened time to manufacture TCR products and decreased overall cost associated with the administration of TCR Therapy.
Latest Developmental Activities or News of the TCR Therapy Treatment Landscape
For further information, refer to the detailed TCR Therapy Unmet Needs, TCR Therapy Market Drivers, and TCR Therapy Market Barriers, click here for TCR Therapy Ongoing Clinical Trial Analysis
TCR Therapy Emerging Drugs Profile
GSK3377794: GlaxoSmithKline
Letetresgene autoleucel (GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor (TCR) engineered T-cells. GSK has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794). Upon exercise of this option and transition of the programme, GSK has assumed responsibility for all development, manufacturing and commercialization activities for the asset. GSK3377794 has been granted PRIME designation by the European Medicines agency and Breakthrough Therapy Designation by the US Food and Drug Administration. It is currently being evaluated in Phase II clinical trial to treat non-small cell lung cancer.
BPX-701: Bellicum Pharmaceuticals
BPX-701 is a CaspaCIDe®-enabled natural high affinity T cell receptor (TCR) product candidate designed to target malignant cells expressing the preferentially-expressed antigen in melanoma (PRAME). Initial planned indications for BPX-701 development are Refractory or Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) with an additional study planned for metastatic uveal melanoma. In vitro study data showed that BPX-701 demonstrated strong affinity to panels of cancer cells presenting PRAME peptides and low affinity to non-tumor cells, as well as complete elimination of BPX-701 cells in response to rimiducid. It is being investigated in Phase I/II stage of development.
MDG1011: Medigene AG
MDG1011 is Medigene’s first proprietary, clinical stage TCR immunotherapy product candidate. The TCR-modified T cell product targeting the tumor antigen PRAME (PReferentially expressed Antigen in MElanoma) is being tested in a Phase I/II clinical trial in approximately 92 blood cancer patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or multiple myeloma (MM).
TCR Therapy Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing therapies for TCR Therapy. The companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.
Request a sample and discover the recent advances in TCR Therapy Ongoing Clinical Trial Analysis and Medications, click here @ TCR Therapy Treatment Landscape
Scope of the TCR Therapy Pipeline Report
Dive deep into rich insights for drugs for TCR Therapy Market Drivers and TCR Therapy Market Barriers, click here @ TCR Therapy Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on TCR Therapy Mergers and acquisitions, TCR Therapy Licensing Activities @ TCR Therapy Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
